肿瘤细胞对肿瘤微环境的影响

doi:10.3760/cma.j.cn371439-20201216-00081

摘要/Abstract

摘要：

肿瘤细胞与肿瘤微环境(TME)关系密切。目前已知多种因素会改变TME影响肿瘤发展,然而TME的改变也离不开肿瘤细胞。越来越多的研究证实,调节TME是抗肿瘤治疗的关键,因此了解肿瘤细胞对TME的影响十分重要。

Abstract:

Tumor cells and tumor microenvironment (TME) are closely related. It is known that many factors will change the TME, then affect tumor development, however the change of TME is also inseparable from tumor cells. More and more studies have confirmed that the regulation of TME is the key to anti-tumor therapy. Therefore, it is critical to understand the effect of tumor cells on TME.

Key words: Tumor microenvironment, Neoplastic cells

周邓婧, 姚颐, 宋启斌, 吴彬, 肖梦霞, 杨思琦. 肿瘤细胞对肿瘤微环境的影响[J]. 国际肿瘤学杂志, 2021, 48(7): 424-428.

Zhou Dengjing, Yao Yi, Song Qibin, Wu Bin, Xiao Mengxia, Yang Siqi. Effect of tumor cells on tumor microenvironment[J]. Journal of International Oncology, 2021, 48(7): 424-428.

参考文献 43

[1]	Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy[J]. Nat Med, 2018, 24(5):541-550. DOI: 10.1038/s41591-018-0014-x. doi: 10.1038/s41591-018-0014-x pmid: 29686425
[2]	Strong AL, Pei DT, Hurst CG, et al. Obesity enhances the conversion of adipose-derived stromal/stem cells into carcinoma-associated fibroblast leading to cancer cell proliferation and progression to an invasive phenotype[J]. Stem Cells Int, 2017, 2017:9216502. DOI: 10.1155/2017/9216502. doi: 10.1155/2017/9216502 pmid: 29527228
[3]	董熠, 姚颐, 宋启斌, 等. 癌相关成纤维细胞的分化来源[J]. 国际肿瘤学杂志, 2017, 44(2):125-128. DOI: 10.3760/cma.j.issn.1673-422X.2017.02.012.
[4]	Wang L, Cao L, Wang H, et al. Cancer-associated fibroblasts enhance metastatic potential of lung cancer cells through IL-6/STAT3 signaling pathway[J]. Oncotarget, 2017, 8(44):76116-76128. DOI: 10.18632/oncotarget.18814. doi: 10.18632/oncotarget.v8i44
[5]	Hardy SD, Shinde A, Wang WH, et al. Regulation of epithelial-mesenchymal transition and metastasis by TGF-β, P-bodies, and autophagy[J]. Oncotarget, 2017, 8(61):103302-103314. DOI: 10.18632/oncotarget.21871. doi: 10.18632/oncotarget.v8i61
[6]	Zhou P, Li B, Liu F, et al. The epithelial to mesenchymal transition (EMT) and cancer stem cells: implication for treatment resistance in pancreatic cancer[J]. Mol Cancer, 2017, 16(1):52. DOI: 10.1186/s12943-017-0624-9. doi: 10.1186/s12943-017-0624-9
[7]	Cazet AS, Hui MN, Elsworth BL, et al. Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer[J]. Nat Commun, 2018, 9(1):2897. DOI: 10.1038/s41467-018-05220-6. doi: 10.1038/s41467-018-05220-6
[8]	Öhlund D, Handly-Santana A, Biffi G, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer[J]. J Exp Med, 2017, 214(3):579-596. DOI: 10.1084/jem.20162024. doi: 10.1084/jem.20162024
[9]	Ringuette GC, Bernard G, Tremblay S, et al. Exosomes induce fibroblast differentiation into cancer-associated fibroblasts through TGFβ signaling[J]. Mol Cancer Res, 2018, 16(7):1196-1204. DOI: 10.1158/1541-7786.MCR-17-0784. doi: 10.1158/1541-7786.MCR-17-0784
[10]	Clocchiatti A, Ghosh S, Procopio MG, et al. Androgen receptor functions as transcriptional repressor of cancer-associated fibroblast activation[J]. J Clin Invest, 2018, 128(12):5531-5548. DOI: 10.1172/JCI99159. doi: 10.1172/JCI99159
[11]	Cho C, Mukherjee R, Peck AR, et al. Cancer-associated fibroblasts downregulate type Ⅰ interferon receptor to stimulate intratumoral stromagenesis[J]. Oncogene, 2020, 39(38):6129-6137. DOI: 10.1038/s41388-020-01424-7. doi: 10.1038/s41388-020-01424-7
[12]	Kuo MC, Kuo PC, Mi Z. Myeloid zinc finger-1 regulates expression of cancer-associated fibroblast and cancer stemness profiles in breast cancer[J]. Surgery, 2019, 166(4):515-523. DOI: 10.1016/j.surg.2019.05.042. doi: 10.1016/j.surg.2019.05.042
[13]	Laklai H, Miroshnikova YA, Pickup MW, et al. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression[J]. Nat Med, 2016, 22(5):497-505. DOI: 10.1038/nm.4082. doi: 10.1038/nm.4082
[14]	Xue J, Yu X, Xue L, et al. Intrinsic β-catenin signaling suppresses CD8⁺ T-cell infiltration in colorectal cancer[J]. Biomed Pharmacother, 2019, 115:108921. DOI: 10.1016/j.biopha.2019.108921. doi: 10.1016/j.biopha.2019.108921
[15]	Pistillo MP, Fontana V, Morabito A, et al. Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study[J]. Cancer Immunol Immunother, 2019, 68(1):97-107. DOI: 10.1007/s00262-018-2258-1. doi: 10.1007/s00262-018-2258-1
[16]	Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer[J]. N Engl J Med, 2016, 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. doi: 10.1056/NEJMoa1606774
[17]	Whelan S, Ophir E, Kotturi MF, et al. PVRIG and PVRL2 are induced in cancer and inhibit CD8⁺ T-cell function[J]. Cancer Immunol Res, 2019, 7(2):257-268. DOI: 10.1158/2326-6066.CIR-18-0442. doi: 10.1158/2326-6066.CIR-18-0442
[18]	Duan S, Guo W, Xu Z, et al. Natural killer group 2D receptor and its ligands in cancer immune escape[J]. Mol Cancer, 2019, 18(1):29. DOI: 10.1186/s12943-019-0956-8. doi: 10.1186/s12943-019-0956-8
[19]	Zhang J, Larrocha PS, Zhang B, et al. Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC⁺ tumors respond to PD1/PD-L1 blockade therapy[J]. J Immunother Cancer, 2019, 7(1):223. DOI: 10.1186/s40425-019-0693-y. doi: 10.1186/s40425-019-0693-y
[20]	Li R, Li H, Sun Q, et al. Indoleamine 2,3-dioxygenase regulates T cell activity through Vav1/Rac pathway[J]. Mol Immunol, 2017, 81:102-107. DOI: 10.1016/j.molimm.2016.11.018. doi: 10.1016/j.molimm.2016.11.018
[21]	Ehrlich AK, Pennington JM, Tilton S, et al. AhR activation increases IL-2 production by alloreactive CD4⁺ T cells initiating the differentiation of mucosal-homing Tim3⁺ Lag3⁺ Tr1 cells[J]. Eur J Immunol, 2017, 47(11):1989-2001. DOI: 10.1002/eji.201747121. doi: 10.1002/eji.201747121
[22]	Ham S, Lima LG, Lek E, et al. The impact of the cancer microenvironment on macrophage phenotypes[J]. Front Immunol, 2020, 11:1308. DOI: 10.3389/fimmu.2020.01308. doi: 10.3389/fimmu.2020.01308
[23]	Quero L, Hanser E, Manigold T, et al. TLR2 stimulation impairs anti-inflammatory activity of M2-like macrophages, generating a chimeric M1/M2 phenotype[J]. Arthritis Res Ther, 2017, 19(1):245. DOI: 10.1186/s13075-017-1447-1. doi: 10.1186/s13075-017-1447-1
[24]	Makita N, Hizukuri Y, Yamashiro K, et al. IL-10 enhances the phenotype of M2 macrophages induced by IL-4 and confers the ability to increase eosinophil migration[J]. Int Immunol, 2015, 27(3):131-141. DOI: 10.1093/intimm/dxu090. doi: 10.1093/intimm/dxu090
[25]	Lavender N, Yang J, Chen SC, et al. The Yin/Yan of CCL2: a minor role in neutrophil anti-tumor activity in vitro but a major role on the outgrowth of metastatic breast cancer lesions in the lung in vivo[J]. BMC Cancer, 2017, 17(1):88. DOI: 10.1186/s12885-017-3074-2. doi: 10.1186/s12885-017-3074-2 pmid: 28143493
[26]	Kitamura T, Qian BZ, Soong D, et al. CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages[J]. J Exp Med, 2015, 212(7):1043-1059. DOI: 10.1084/jem.20141836. doi: 10.1084/jem.20141836
[27]	Wang Q, He Z, Huang M, et al. Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2ɑ[J]. Nat Commun, 2018, 9(1):559. DOI: 10.1038/s41467-018-03050-0. doi: 10.1038/s41467-018-03050-0
[28]	Pirro M, Schoof E, van Vliet SJ, et al. Glycoproteomic analysis of MGL-binding proteins on acute T-cell leukemia cells[J]. J Proteome Res, 2019, 18(3):1125-1132. DOI: 10.1021/acs.jproteome.8b00796. doi: 10.1021/acs.jproteome.8b00796
[29]	Swierczak A, Mouchemore KA, Hamilton JA, et al. Neutrophils: important contributors to tumor progression and metastasis[J]. Cancer Metastasis Rev, 2015, 34(4):735-751. DOI: 10.1007/s10555-015-9594-9. doi: 10.1007/s10555-015-9594-9
[30]	Shaul ME, Levy L, Sun J, et al. Tumor-associated neutrophils display a distinct N1 profile following TGFβ modulation: a transcriptomics analysis of pro- vs. antitumor TANs[J]. Oncoimmunology, 2016, 5(11):e1232221. DOI: 10.1080/2162402X.2016.1232221. doi: 10.1080/2162402X.2016.1232221
[31]	Andzinski L, Kasnitz N, Stahnke S, et al. Type Ⅰ IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human[J]. Int J Cancer, 2016, 138(8):1982-1993. DOI: 10.1002/ijc.29945. doi: 10.1002/ijc.29945 pmid: 26619320
[32]	Meyer MA, Baer JM, Knolhoff BL, et al. Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance[J]. Nat Commun, 2018, 9(1):1250. DOI: 10.1038/s41467-018-03600-6. doi: 10.1038/s41467-018-03600-6
[33]	Martinek J, Wu TC, Cadena D, et al. Interplay between dendritic cells and cancer cells[J]. Int Rev Cell Mol Biol, 2019, 348:179-215. DOI: 10.1016/bs.ircmb.2019.07.008. doi: S1937-6448(19)30071-1 pmid: 31810553
[34]	Gringhuis SI, Kaptein TM, Wevers BA, et al. Fucose-based PAMPs prime dendritic cells for follicular T helper cell polarization via DC-SIGN-dependent IL-27 production[J]. Nat Commun, 2014, 5:5074. DOI: 10.1038/ncomms6074. doi: 10.1038/ncomms6074 pmid: 25278262
[35]	Karaman S, Leppanen VM, Alitalo K. Vascular endothelial growth factor signaling in development and disease[J]. Development, 2018, 145(14): dev151019. DOI: 10.1242/dev.151019.
[36]	Huang C, Chen Y. Lymphangiogenesis and colorectal cancer[J]. Saudi Med J, 2017, 38(3):237-244. DOI: 10.15537/smj.2017.3.16245. doi: 10.15537/smj.2017.3.16245
[37]	Zhao Y, Adjei AA. Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor[J]. Oncologist, 2015, 20(6):660-673. DOI: 10.1634/theoncologist.2014-0465. doi: 10.1634/theoncologist.2014-0465
[38]	Heinolainen K, Karaman S, D'Amico G, et al. VEGFR3 modulates vascular permeability by controlling VEGF/VEGFR2 signaling[J]. Circ Res, 2017, 120(9):1414-1425. DOI: 10.1161/CIRCRESAHA.116.310477. doi: 10.1161/CIRCRESAHA.116.310477
[39]	Liu Y, Li T, Hu D, et al. NOK/STYK1 promotes the genesis and remodeling of blood and lymphatic vessels during tumor progression[J]. Biochem Biophys Res Commun, 2016, 478(1):254-259. DOI: 10.1016/j.bbrc.2016.07.059. doi: 10.1016/j.bbrc.2016.07.059
[40]	Dobbs JL, Shin D, Krishnamurthy S, et al. Confocal fluorescence microscopy to evaluate changes in adipocytes in the tumor microenvironment associated with invasive ductal carcinoma and ductal carcinoma in situ[J]. Int J Cancer, 2016, 139(5):1140-1149. DOI: 10.1002/ijc.30160. doi: 10.1002/ijc.30160
[41]	Zhang M, Di Martino JS, Bowman RL, et al. Adipocyte-derived lipids mediate melanoma progression via FATP proteins[J]. Cancer Discov, 2018, 8(8):1006-1025. DOI: 10.1158/2159-8290.CD-17-1371. doi: 10.1158/2159-8290.CD-17-1371
[42]	Sakurai M, Miki Y, Takagi K, et al. Interaction with adipocyte stromal cells induces breast cancer malignancy via S100A7 upregulation in breast cancer microenvironment[J]. Breast Cancer Res, 2017, 19(1):70. DOI: 10.1186/s13058-017-0863-0. doi: 10.1186/s13058-017-0863-0 pmid: 28629450
[43]	Wei X, Li S, He J, et al. Tumor-secreted PAI-1 promotes breast cancer metastasis via the induction of adipocyte-derived collagen remodeling[J]. Cell Commun Signal, 2019, 17(1):58. DOI: 10.1186/s12964-019-0373-z. doi: 10.1186/s12964-019-0373-z